Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 832

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 832
---
 in Lod, the TASE, and the Israel Securities Authority. B. Kadimastem and NLS report on a private fundraising of up to USD $3 million for NLS and the signing of a framework agreement for an investment of USD $25 million in NLS. On March 31, 2025, the Company, along with NLS, announced an additional private fundraising round for NLS in the amount of USD $3 million at a share price of USD $1.65, reflecting a premium of 10% over the NLS share price (hereinafter, “the fundraising”), with USD $2 million of the total fundraising completed as of the date of [these financial statements], and the remaining amount of up to USD $1 million, subject to the registration of the Shares and the approval of the NLS shareholders’ meeting, as part of the actions being taken towards completion. At the same time, a framework agreement for an investment of USD $25 million in NLS was also signed. Annex G-44 KADIMASTEM LTD.
NOTES TO FINANCIAL STATEMENTS Note 23: — SUBESEQUENT Events (cont.) The purpose of the aforementioned fundraising efforts is to secure financing for the merger transaction and for post -mergerworking capital, as well as other general objectives. The completion of the fundraising round and the signing of the aforementioned framework agreement for investment, along with the previous private fundraising rounds conducted by NLS in a joint effort with the Company in October 2024 and January 2025, amount to a total of approximately USD $6.7 million, as well as an additional future investment framework of USD $25 million. These represent a significant milestone in the efforts to complete the merger transaction, strengthen the equity of the Merged Company, and develop the Company’s products following the completion of the merger transaction, including the conduct of clinical trials. C. Conversion Notice re- Convertible Loan into Company Shares, in the Amount of USD $560,479 On April 14, 2025, the Company announced that, Mr. Julien Ruggieri, a significant shareholder in the Company, provided the Company a written notice of his decision to convert the remaining USD $500,000 principal balance of the convertible loan granted by him to the Company, excluding accrued interest of USD $60,479, into 279,952 ordinary shares of the Company, no par value and 349,940 non -listedwarrants, exercisable into ordinary shares (the “Rugg